Drug Profile
Research programme: anti-tubulin agents - Cell Therapeutics
Alternative Names: CT-45099Latest Information Update: 21 Jul 2008
Price :
$50
*
At a glance
- Originator Cell Therapeutics
- Class Small molecules
- Mechanism of Action Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 12 Apr 2006 Preclinical trials in Cancer in USA (unspecified route)